Image
Clinical Research Updates

Caring for Patients with Severe Asthma

Evolving Best Practices to Optimize Outcomes

Clinical Practice Guidelines

Global Strategy for Asthma Management and Prevention

Global Initiative for Asthma (GINA) 2017.

International ERS/ATS Guidelines on Definition, Evaluation and Treatment of Severe Asthma

Chung KF, et al. Eur Respir J. 2014;43(2):343-373.

Patient Resources

Asthma and Allergy Foundation of America (AAFA)

AAFA is dedicated to improving the quality of life for people with asthma and allergic diseases through education, advocacy, and research.

American College of Allergy, Asthma & Immunology (ACAAI)

The ACAAI fosters a culture of collaboration and congeniality in which members work toward the common goals of patient care, education, advocacy, and research.

American College of Physicians (ACP)

The ACP provides a number of resources for patients with asthma, including instructional videos about how to use different types of inhalers.

American Lung Association

The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy, and research.

American Thoracic Society (ATS)

The mission of the ATS is to improve health worldwide by advancing research, clinical care, and public health in respiratory disease, critical illness, and sleep disorders.

Asthma Action Plan

This printable reference tool is designed to help patients know when to use their different asthma medications and when to call their health care providers.

Asthma and Outdoor Air Pollution

This resource provides guidance to patients who are sensitive to air pollution.

Asthma Inhalers

This is a list of different inhaled asthma medications with key information such as prescribing information and tips for proper inhaler technique.

How to Use a Metered-Dose Inhaler

Printed instructions and short videos are provided to aid patients in taking their medication correctly.

My Asthma Wallet Card

This printable card for patients to carry lists important information, such as current medications and health care provider contact information.

Clinical Assessment Tools

Asthma Control Test (ACT)

This 5-question test evaluates asthma control over the past 4 weeks on a 5-point Likert scale. A score of <20 on the ACT suggests asthma that is uncontrolled. Nathan RA, et al. J Allergy Clin Immunol. 2004;113(1):59-65.

Asthma Control Questionnaire (ACQ)

This 7-question assessment tool measures asthma control over the past 7 days. Six questions are self-administered by the patient, and 1 question requires a clinician’s input. Scores range from 1 (totally controlled) to 6 (severely uncontrolled). Juniper EF, et al. Eur Respir J. 1999;14(4):902-907.

Asthma Therapy Assessment Questionnaire (ATAQ)

This 4-question test assesses asthma control over the past 4 weeks. Each question has a possible score of 0 or 1; if the sum of the 4 question scores is >1, the patient’s asthma may be uncontrolled. Vollmer WM, et al. Am J Crit Care Med. 1999;160(5 Pt 1):1647-1652.

Asthma APGAR Tool

This 6-question assessment tool evaluates asthma control over the past 2 weeks. Any combination with a total score >2 is considered not well controlled. Yawn BP, et al. J Asthma Allergy. 2008;1:1-10.

Suggested Readings

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised,double-blind, placebo-controlled, phase 2b trial.

Brightling CE, et al. Lancet Respir Med. 2015;3(9):692-701.

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.

Bleecker ER, et al. Lancet. 2016;388(10056):2115-2127.

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.

Castro M, et al. Lancet Respir Med. 2015;3(5):355-366.

A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma.

D’Amato G, et al. Ther Clin Risk Manag. 2007;3(4):613-619.

Biologics in asthma—the next step towards personalized treatment.

Darveaux J, Busse WW. J Allergy Clin Immunol Pract. 2015;3(2):152-161.

Cluster analysis and clinical asthma phenotypes

Haldar P, et al. Am J Respir Crit Care Med. 2008;178:218-224.

Targeting key proximal drivers of type 2 inflammation in disease.

Gandhi NA, et al. Nat Rev Drug Discov. 2016;15(1):35-50

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.

FitzGerald JM, et al. Lancet. 2016;388(10056):2128-2141.

Adult asthma biomarkers

Kim MA, et al. Curr Opin Allergy Clin Immunol. 2014;14(1):49-54.

Mepolizumab treatment in patients with severe eosinophilic asthma.

Ortega HG, et al. N Engl J Med. 2014;371(13):1198-1207.

Getting control of uncontrolled asthma

Wechsler ME. Am J Med. 2014;127(11):1049-1059.

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.

Wenzel S, et al. Lancet. 2016;388(10039):31-44

Interactive Presentation

Clinical Insights Into Severe Asthma Pathophysiology

Michael Wechsler, MD, MMSc


Caring for Patients with Severe Asthma Teaser

Eugene R. Bleecker, MD; Sidney S. Braman, MD, FCCP; Richard J. Martin, MD


Severe Asthma and the Primary Care Provider Teaser

Michael E. Wechsler, MD, MMSc; Barbara P. Yawn, MD, MSc, FAAFP


Activity
Caring for Patients with Severe Asthma

Evolving Best Practices to Optimize Outcomes

Activity
Confronting the Challenges of Severe Asthma

Improving Patient Outcomes via Coordinated Multidisciplinary Care

Relevant Resources

Acute Management of Migraine Attacks

Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes

Clinical Updates on the Management of Gout

Evidence-Based Strategies for Improved Patient Outcomes

Opioid-Induced Constipation

Proactive Diagnosis and Targeted Management

Chronic Obstructive Pulmonary Disease, Asthma, or Both

Differential Diagnosis and Comprehensive Management Strategies

Improving Outcomes in Chronic Obstructive Pulmonary Disease

Optimizing Maintenance Therapy Across Healthcare Settings

Managing Gout in Primary Care

Evolving Strategies for Diagnosis and Long-Term Management

Clinical Issues in Chronic Pain

Consensus and Controversies for Responsible Opioid Prescribing

Noninsulin Approaches to Managing Type 2 Diabetes

Best Practices in Combination Therapy

Hitting the Target in Type 2 Diabetes

Evolving Approaches to Insulin Based Therapy

Clearing the Air

Improving Outcomes for Patients with COPD

Clinical Updates in Type 2 Diabetes

New Strategies for Insulin Replacement Therapy

How Low Do You Go?

Clinical Updates in LDL-C Management

Incretin-Based Therapies For Type 2 Diabetes

Improving Comprehensive Patient Care

Improving Outcomes in Non–24-Hour Sleep-Wake Disorder

Identifying Patients and Tailoring Therapy

Comprehensive Management of Chronic Obstructive Pulmonary Disease

Collaborative Approaches to Guideline-Concordant Patient Care

Clinical Updates in the Management of Severe Asthma

New Strategies for Individualizing Long-term Care

Comprehensive Chronic Pain Management

A Focus on Patients With Opioid-Induced Constipation

Clinical Issues in Bipolar Depression

Consensus and Controversies Across the Spectrum of Patient Presentations

Improving Outcomes in Severe Asthma

A New Era in Precision Medicine

Clinical Updates in Rheumatoid Arthritis

Evolving Treatment Algorithms and Expert Perspectives on Biosimilars

Clinical Issues in Severe Asthma

Consensus and Controversies on the Road to Precision Medicine